Description
The influenza vaccines market in the United States is poised for significant growth over the next decade, driven by an array of factors including increasing public awareness, governmental policy support, and ongoing technological advancements. Current projections suggest a compound annual growth rate (CAGR) of approximately XX% from 2025 to 2034. This robust growth rate is indicative of a market that is not only expanding but is also adapting to the evolving healthcare landscape.
Market drivers are multifaceted, with heightened awareness surrounding the importance of vaccinations partially fueled by the global pandemic. This surge in public health consciousness is expected to encourage higher vaccination rates among various demographics. Furthermore, the role of healthcare organizations and government initiatives is pivotal. Increased funding for vaccination programs, coupled with outreach initiatives targeting underserved populations, is likely to expand market penetration significantly.
![influenza vaccines]()
However, growth is not devoid of challenges. The influenza vaccines market may encounter hurdles such as vaccine hesitancy in certain populations, fluctuating viral strains necessitating annual updates to vaccine formulations, and regulatory hurdles associated with new vaccine approvals. Stakeholders in the industry must remain vigilant and innovative to address these challenges effectively.
Investment opportunities are ripe as well, particularly in biopharmaceutical companies focused on next-generation vaccine development, including quadrivalent and universal influenza vaccines. The demographic shifts observable in the United States, such as an aging population, are likely to influence vaccination strategies and subsequently benefit the influenza vaccine market. As more individuals seek preventive healthcare services, especially the elderly and those with comorbidities, the demand for influenza vaccinations will only increase.
In summary, the future outlook for the influenza vaccines market presents both opportunities and challenges. With informed investment decisions and strategic focus, stakeholders can harness the market’s growth potential leading up to 2034, contributing to improved public health outcomes across the nation.
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. United States Influenza Vaccines Market Size, Insights, Analysis, and Forecasts (2019 – 2033)
5. United States Number of Persons Vaccinated with Influenza Vaccines (2019 – 2033)
5.1 Number of Children Vaccinated with Influenza Vaccines
5.2 Number of Adults Vaccinated with Influenza Vaccines
6. Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market
6.1 Market Drivers
6.2 Market Challenges
7. United States Influenza Vaccines Pricing Analysis, Trends and Insights
8. United States Influenza Vaccines Production, Supply, and Allocation (By Companies),2014 – 2024
9. United States Influenza Vaccines Distribution and Demand Analysis 2010 – 2024
10. Effectiveness of Influenza Vaccines in the United States, 2004 – 2024
11. Rapid Diagnostic Testing for the Management of Influenza
12. Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States
13. Reimbursement Environment of the United States Influenza Vaccines Market
14. Regulatory Framework of the United States Influenza Vaccines Market
15. Major Deals and Agreement Activities in the Influenza Vaccines Market
15.1 Merger and Acquisitions
15.2 Collaboration Deals
15.3 Licensing Agreement
15.4 Exclusive Agreement
15.5 Distribution Agreement
16. Promising Influenza Vaccines in the Clinical Development
17. Influenza Vaccines Clinical Trial Insights by Phase, Company and Country
17.1 Year 2024
17.2 Year 2023
17.3 Year 2022
17.4 Year 2021
18. Key Company Profiles
18.1 Sanofi Pasteur
18.1.1 Business Overview
18.1.2 Influenza Vaccines Portfolio
18.1.3 Influenza Vaccines Sales Value Analysis
18.1.4 Promising Influenza Vaccines in the Clinical Development
18.1.5 Recent Development
18.2 GlaxoSmithKline (GSK)
18.2.1 Business Overview
18.2.2 Influenza Vaccines Portfolio
18.2.3 Influenza Vaccines Sales Value Analysis
18.2.4 Recent Development
18.3 Seqirus
18.3.1 Business Overview
18.3.2 Influenza Vaccines Portfolios
18.3.3 Influenza Vaccines Sales Value Analysis
18.3.4 Promising Influenza Vaccines in the Clinical Development
18.3.5 Recent Development
18.4 AstraZeneca
18.4.1 Business Overview
18.4.2 Influenza Vaccines Portfolio
18.4.3 Influenza Vaccines Sales Value Analysis
18.4.4 Recent Development
19. Emerging Company Profiles
19.1 Novavax
19.1.1 Business Overview
19.1.2 Promising Influenza Vaccines in the Clinical Development
19.1.3 Recent Development
19.2 BiondVax Pharmaceuticals Ltd.
19.2.1 Business Overview
19.2.2 Promising Influenza Vaccines in the Clinical Development
19.2.3 Recent Development
19.3 Medicago
19.3.1 Business Overview
19.3.2 Promising Influenza Vaccines in the Clinical Development
19.3.3 Recent Development
19.4 Moderna Inc
19.4.1 Business Overview
19.4.2 Promising Influenza Vaccines in the Clinical Development
19.4.3 Recent Development
19.5 Pneumagen
19.5.1 Business Overview
19.5.2 Promising Influenza Vaccines in the Clinical Development
19.5.3 Recent Development
19.6 Altimmune
19.6.1 Business Overview
19.6.2 Promising Influenza Vaccines in the Clinical Development
19.6.3 Recent Development
19.7 Daiichi Sankyo
19.7.1 Business Overview
19.7.2 Promising Influenza Vaccines in the Clinical Development
19.7.3 Recent Development
19.8 FluGen
19.8.1 Business Overview
19.8.2 Promising Influenza Vaccines in the Clinical Development
19.8.3 Recent Development
19.9 Imutex
19.9.1 Business Overview
19.9.2 Promising Vaccines in the Clinical Development
19.9.3 Recent Development
19.10 EpiVax
19.10.1 Business Overview
19.10.2 Promising Influenza Vaccines in the Clinical Development
19.10.3 Recent Development
19.11 Versatope Therapeutics, Inc.
19.11.1 Business Overview
19.11.2 Promising Influenza Vaccines in the Clinical Development
19.11.3 Recent Development
20. Appendix
20.1 About DPI Research
20.2 Glossary of Terms
List of Tables:
Table 7-1: United States Pediatric Influenza Vaccines Price, 2023 – 2024
Table 7-2: United States Adult Influenza Vaccines Price, 2023 – 2024
Table 8-1: United States Influenza Vaccines Production, Supply, and Allocation
Table 9-1: Total Percentage of Influenza Vaccines Released by Week, 2023 – 2024
Table 9-2: Total Percentage of Influenza Vaccines Released by Week, 2022 – 2023
Table 9-3: Total Percentage of Influenza Vaccines Released by Week, 2021 – 2022
Table 9-4: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021
Table 9-5: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 9-6: Total Percentage of Influenza Vaccines Released by Week, 2018 – 2019
Table 9-7: Total Percentage of Influenza Vaccines Released by Week, 2017 – 2018
Table 9-8: Total Percentage of Influenza Vaccines Released by Week, 2016 – 2017
Table 10-1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2024
Table 11-1: Influenza Virus Testing Methods
Table 12-1: Distribution of Influenza Vaccination
Table 14-1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 15-1: Merger & Acquisitions in the Influenza Vaccines Market
Table 15-2: Collaboration Deal in the Influenza Vaccines Market
Table 15-3: Licensing Agreement in the Influenza Vaccines Market
Table 15-4: Exclusive Agreement in the Influenza Vaccines Market
Table 15-5: Distribution Agreement in the Influenza Vaccines Market
Table 16-1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 18-1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 18-2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 19-1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 19-2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 19-3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 19-4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 19-5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 19-6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 19-7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 19-8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 19-9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 19-10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 19-11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures:
Figure 2-1: United States Influenza Vaccines Market Size and Analysis (Million US$),2019 – 2024
Figure 2-2: United States Influenza Vaccines Market Size and Forecast (Million US$),2025 – 2033
Figure 3-1: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2019 – 2024
Figure 3-2: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2025 – 2033
Figure 3-3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2019 – 2024
Figure 3-4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2025 – 2033
Figure 3-5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2019 – 2024
Figure 3-6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2025 – 2033
Figure 7-1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2024
Figure 10-1: United States Place of Influenza Vaccination for Children and Adults (Percent),2021 – 2024
Figure 16-1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2019 – 2024
Figure 16-2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2025 – 2033
Figure 16-3: GSK Influenza Vaccines Net Sales Value (Million US$),2019 – 2024
Figure 16-4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2025 – 2033
Figure 16-5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2019 – 2024
Figure 16-6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2025 – 2033
Figure 16-7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2019 – 2024
Figure 16-8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2025 – 2033
Liam (verified owner) –
Good quality.
Mason (verified owner) –
The product is firmly packed.
Avery (verified owner) –
The product is firmly packed.
Henry (verified owner) –
The product is firmly packed.
Liam (verified owner) –
Good service.
Phoenix (verified owner) –
The product is firmly packed.
Mateo (verified owner) –
Good service.
William (verified owner) –
Very fast delivery.
Kaden Arabic (verified owner) –
The product is firmly packed.
Dylan (verified owner) –
Good quality.